

**NEW!**

**Senvelgo** 

# Just what cats ordered

*A convenient, once-daily, oral solution for diabetes*



**Senvelgo®'s novel approach means you can now treat diabetes without injecting insulin**

- ◆ Simple dosing according to bodyweight
- ◆ Reduced risk of clinical hypoglycaemia
- ◆ Glycaemic control can be achieved within a week<sup>1,2</sup>

**Make Senvelgo® your new, simple solution for diabetic cats and their owners**



Scan to learn more!



Senvelgo® 15 mg/ml oral solution is indicated to reduce hyperglycaemia in non-insulin dependent diabetic cats. Prior to treatment start, careful patient selection, and thereafter monitoring for diabetic ketoacidosis (DKA) is important.

 **Boehringer  
Ingelheim**

# Watch our new Senvelgo® webinar and earn free CPD!

As part of the launch toolkit, this new Senvelgo® webinar 'How to manage diabetes in cats with Senvelgo®' is hosted by Dr Teen Presnail BVSc (Hons) CertVOphthal MRCVS, who will introduce you to Senvelgo®, our new breakthrough treatment for diabetes, and guide you through how to best use Senvelgo® to successfully manage feline diabetes in your practice.



Scan to watch and earn free CPD!

## Senvelgo® toolkit

To support you with prescribing Senvelgo®, we have produced a new Senvelgo® toolkit which includes a veterinary management guide, CPD webinar, cat owner leaflet and homecare journal.



For more information and to access these materials, visit [senvelgo.vet](https://senvelgo.vet)

## Veterinary support

A team of 8 vets and 5 veterinary nurses with over 140 years' combined experience.

### Case discussions and product advice

UK: 01344 746957 IE: 01 291 3985

[vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com)

### NEW live chat service

[senvelgo.vet](https://senvelgo.vet)

### Service hours

Mon-Thu 9am-5pm

Fri 9am-4.30pm

Emergencies 24/7 (via telephone only)

### Virtual team meetings

A technical vet can attend a meeting via Microsoft Teams or Zoom



\*Best-in-class animal health pharmaceutical company for technical support helpline in 2022. CM Research 2022<sup>3</sup>

**Speak to your Boehringer Ingelheim Territory Manager for more information!**

1. Niessen, S. J. M. et al. (2022) Once daily oral therapy for feline diabetes mellitus: evaluation of SGLT-2 inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats. *Journal of Veterinary Internal Medicine* 36, 2512–2513.
2. Sparkes, A. H. et al. (2015) ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats. *J Feline Med Surg* 17, 235–50.
3. CM Research (2022) Small animal vets UK April 2022. Syndicated Sales Rep Survey.

Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK(NI): POM-VIE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK(NI) Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: [vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com). Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2024 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Mar 2024. UI-PET-0030-2024. Use Medicines Responsibly.

